Disease relevance of Pivagabine

• In conclusion, in patients with hypothalamic amenorrhea related to weight loss pivagabine induced a significant decrease of cortisol secretion and an increase of GH release by pivagabine administration, suggesting that this drug exerts a specific neuroendocrine modulatory role [1].
• Effect of pivagabine on stress-induced gastric ulcer formation in rats [2].
• Pivagabine determined a significant reduction in the number of animals with gastric lesions (5 vs. 10, p < 0.05), in the linear extension of ulcers (2.0 +/- 0.8 vs. 7.2 +/- 1.7 mm, percent protection 72.2, p < 0.05) and in the linear extension of hemorrhages (2.6 +/- 1.0 vs. 10.3 +/- 1.6 mm, percent protection 74.8, p < 0.01) [2].

Psychiatry related information on Pivagabine

• Pivagabine effects on neuroendocrine responses to experimentally-induced psychological stress in humans [3].
• Randomised, double-blind, placebo-controlled study of pivagabine in neurasthenia [4].
• Evaluation of the efficacy of pivagabine on insomnia associated with mood disorders [5].
• Clinical evaluation of the efficacy of pivagabine in the treatment of mood and adjustment disorders [6].
• Moreover, pivagabine has a highly significant therapeutic potential in clinical conditions characterized by manifestations of psychological distress due to an inadequate management of stressful events [7].

High impact information on Pivagabine

• Antagonism by pivagabine of stress-induced changes in GABAA receptor function and corticotropin-releasing factor concentrations in rat brain [8].
• Pivagabine-induced increases in the abundance of CRF mRNA in the cerebral cortex and hypothalamus of rats [9].
• The effect of treatment of rats with pivagabine (4-[(2,2-dimethyl-1-oxopropyl) amino] butanoic acid) for 4 days on the abundance of corticotropin-releasing factor (CRF) mRNA in the brain was investigated [9].
• LH, FSH and PRL levels were not modified by placebo or pivagabine administration [1].
• Oral treatment with 1800 mg pivagabine lasting 30 days showed in both groups a significant improvement of the psychic state with variations from 50 to 80% of the criteria reported in the Hamilton Rating Scale for Depression (HDRS) and for anxiety (HARS) and in the Self-rating Anxiety Scale (SAS) [6].

Biological context of Pivagabine

• Role of pivagabine in the treatment of climacteric syndrome [10].

Anatomical context of Pivagabine

• These results demonstrate that pivagabine increases the amount of CRF mRNA in both the hypothalamus and cerebral cortex of rats, effects that might be relevant to the action of this drug in preventing the stress-induced changes in CRF hypothalamic concentration [9].

Gene context of Pivagabine

• A double-blind, placebo-controlled study was performed in order to evaluate the efficacy of pivagabine (4-[(2,2-dimethyl-1-oxopropyl)amino]butanoic acid, CAS 69542-93-4, Tonerg) on "distress" in children hospitalized for acute disorders [11].
• The results shown in the present study were positive and likely attributable to the inhibitory modulating activity of pivagabine on corticotropin releasing factor secretion, that is considered to be responsible for insomnia associated with anxiety or coexisting anxiety and depression, observed in patients with chronic stress [5].
• It is likely that the observed effects of pivagabine are mediated by inhibition of release of corticotropin-releasing factor, a neurohormone involved in stress-generating mechanisms [12].
• One hundred and eighteen patients with neurasthenia, as defined by ICD 10 (International Classification of Diseases), participated in a randomised, double-blind, placebo-controlled trial of pivagabine (4-[(2,2-dimethyl-1-oxopropyl)amino]butanoic acid, CAS 69542-93-4, Tonerg) [4].

Analytical, diagnostic and therapeutic context of Pivagabine

• Use of pivagabine in the management of hospitalization distress in children [11].
• Pivagabine induced significantly greater improvement in all the items listed above as compared to the control group [11].

References